Revol Bruno, Gautier-Veyret Elodie, Arrivé Capucine, Fouilhé Sam-Laï Nathalie, McLeer-Florin Anne, Pluchart Hélène, Pinsolle Julian, Toffart Anne-Claire
Centre Régional de Pharmacovigilance, Pôle Santé Publique, CHU Grenoble Alpes, France.
HP2, INSERM U1042, Université Grenoble Alpes, France.
Br J Clin Pharmacol. 2020 Sep;86(9):1892-1893. doi: 10.1111/bcp.13862. Epub 2019 Jan 30.
The use of complementary and alternative medicine at least once during or after cancer treatment has increased over the past years from an estimated 25% in the 1970s and 1980s to more than 32% in the 1990s and to 49% after 2000. The risk of herb-drug interaction is therefore increasingly recognized as a public health problem. To the best of our knowledge, we report here the first case of interaction between ginger and anticancer drug, with serious consequences for the patient. There is an urgent need regarding complementary and alternative medicine: Both clinicians and patients should be aware of the potential interactions between herbs and prescribed drugs.
在过去几年中，癌症治疗期间或之后至少使用一次补充和替代医学的情况有所增加，从20世纪70年代和80年代估计的25%增至20世纪90年代的32%以上，并在2000年之后达到49%。因此，草药与药物相互作用的风险日益被视为一个公共卫生问题。据我们所知，我们在此报告首例生姜与抗癌药物相互作用的病例，对患者造成了严重后果。补充和替代医学方面存在迫切需求：临床医生和患者都应意识到草药与处方药之间的潜在相互作用。
